Physician profile
Anjana Samadder
NPI 1811053309
$13,631.60
in general payments reported to CMS, 2019-2025
28 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,818 · 2020: $350 · 2021: $2,414 · 2022: $1,511 · 2023: $3,848 · 2024: $1,060 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Education | $111.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,850.40 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $1,252.98 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Janssen Biotech, INC. | $958.72 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Abbvie INC. | $738.21 | 2019-2025 | Linzess |
| Ironwood Pharmaceuticals, INC | $723.53 | 2019-2025 | Linzess |
| Genzyme Corporation | $596.46 | 2022-2025 | |
| Ardelyx, INC. | $468.41 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $366.56 | 2019-2025 | Eohilia |
| Nestle Healthcare Nutrition INC. | $295.84 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $295.73 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $156.66 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $155.33 | 2019-2022 | |
| Gilead Sciences, INC. | $131.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $124.75 | 2019-2024 | Dificid |
| Evoke Pharma, INC. | $99.21 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $65.14 | 2019 | |
| Capsovision, INC. | $63.50 | 2024 | Capsocam Plus |
| Concordia Pharmaceuticals INC. | $47.39 | 2019 | |
| Pfizer INC. | $46.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $45.44 | 2021 | |
| Lucid Diagnostics INC. | $30.42 | 2021-2022 | |
| Braintree Laboratories, INC. | $26.23 | 2019-2023 | Suflave |
| Novo Nordisk INC | $22.24 | 2025 | Wegovy |
| Ethicon US, LLC | $17.99 | 2019 | |
| Aimmune Therapeutics, INC. | $16.88 | 2024 | |
| Medtronic, INC. | $13.10 | 2021 | |
| Alfasigma USA, INC. | $12.92 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $9.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjana Samadder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.